Background: Podocyte injury is a hallmark of minimal change disease (MCD). Calcineurin inhibitors have been widely used in the current treatment of MCD, and miR-499 may target calcineurin. We aimed to study the function of miR-499 in MCD and test whether miR-499 delivery can improve MCD. Methods: An MCD mouse model was generated using puromycin aminonucleoside (PAN). MiR-499 was delivered using lentiviruses. Biochemical indicators including serum albumin, triglyceride, cholesterol, and 24-h urine protein were determined. Targets of miR-499 were confirmed using reporter gene activity assays. The ultrastructure of podocytes was analyzed using transmission electron microscopy. Results: MiR-499 significantly improved MCD-related symptoms and signs. Foot-process effacement was caused by PAN and partially reversed by miR-499. We identified that both CnAα and CnAβ were targets of miR-499, and were overexpressed in the presence of PAN. However, miR-499 reduced the expression of CnAα and CnAβ, leading to a decreased activity of calcineurin signaling in mouse podocytes in vitro and in vivo. In addition, miR-499 recovered PAN-induced reduction of cell viability. Conclusions: MiR-499 ameliorated podocyte injury by targeting CnAα and CnAβ in a PAN-induced MCD mouse model. Delivery of miR-499 can be a novel strategy for MCD treatment.

Keywords:
Minimal change disease, Lipid nephrosis, Podocyte, miR-499, MicroRNA therapy
1.
Vivarelli M, Massella L, Ruggiero B, Emma F: Minimal change disease. Clin J Am Soc Nephrol 2017; 12: 332–345.
2.
Hogan J, Radhakrishnan J: The treatment of minimal change disease in adults. J Am Soc Nephrol 2013; 24: 702–711.
3.
Saleem MA, Kobayashi Y: Cell biology and genetics of minimal change disease. F1000Res 2016; 5:pii:F1000 Faculty Rev-412.
4.
Tian X, Ishibe S: Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease. Nephrol Dial Transplant 2016; 31: 1577–1583.
5.
Schonenberger E, Ehrich JH, Haller H, Schiffer M: The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26: 18–24.
6.
Sommerer C, Giese T: Nuclear factor of activated T cells-regulated gene expression as predictive biomarker of personal response to calcineurin inhibitors. Ther Drug Monit 2016; 38(suppl 1):S50–S56.
7.
Hogan PG, Chen L, Nardone J, Rao A: Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205–2232.
8.
Rusnak F, Mertz P: Calcineurin: form and function. Physiol Rev 2000; 80: 1483–1521.
9.
Shen X, Jiang H, Ying M, Xie Z, Li X, Wang H, Zhao J, Lin C, Wang Y, Feng S, Shen J, Weng C, Lin W, Wang H, Zhou Q, Bi Y, Li M, Wang L, Zhu T, Huang X, Lan HY, Zhou J, Chen J: Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 2016; 6: 32087.
10.
Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931–938.
11.
Sinha A, Sharma A, Mehta A, Gupta R, Gulati A, Hari P, Dinda AK, Bagga A: Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome. Indian J Nephrol 2013; 23: 41–46.
12.
Rupaimoole R, Slack FJ: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017; 16: 203–222.
13.
Liu J, Liang X, Zhou D, Lai L, Xiao L, Liu L, Fu T, Kong Y, Zhou Q, Vega RB, Zhu MS, Kelly DP, Gao X, Gan Z: Coupling of mitochondrial function and skeletal muscle fiber type by a miR-499/Fnip1/AMPK circuit. EMBO Mol Med 2016; 8: 1212–1228.
14.
Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW 2nd: Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res 2012; 111: 521–531.
15.
Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, Li YR, Li PF: miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011; 17: 71–78.
16.
Agarwal V, Bell GW, Nam JW, Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 4.
17.
Zhou K, Fan YD, Wu PF, Duysenbi S, Feng ZH, Du GJ, Zhang TR: MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. Onco Targets Ther 2017; 10: 1625–1635.
18.
Crabtree GR, Olson EN: NFAT signaling: choreographing the social lives of cells. Cell 2002; 109(suppl):S67–S79.
19.
Zhang X, Gee H, Rose B, Lee CS, Clark J, Elliott M, Gamble JR, Cairns MJ, Harris A, Khoury S, Tran N: Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer 2016; 16: 86.
20.
Yeung F, Chung E, Guess MG, Bell ML, Leinwand LA: Myh7b/miR-499 gene expression is transcriptionally regulated by MRFs and Eos. Nucleic Acids Res 2012; 40: 7303–7318.
21.
Ding F, Li X, Li B, Guo J, Zhang Y, Ding J: Calpain-mediated cleavage of calcineurin in puromycin aminonucleoside-induced podocyte injury. PLoS One 2016; 11:e0155504.
22.
Gooch JL, Toro JJ, Guler RL, Barnes JL: Calcineurin A-alpha but not a-beta is required for normal kidney development and function. Am J Pathol 2004; 165: 1755–1765.
23.
Moz Y, Levi R, Lavi-Moshayoff V, Cox KB, Molkentin JD, Silver J, Naveh-Many T: Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol 2004; 15: 2972–2980.
24.
Chugh SS, Clement LC, Mace C: New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 2012; 59: 284–292.
25.
Srivastava T, Sharma M, Yew KH, Sharma R, Duncan RS, Saleem MA, McCarthy ET, Kats A, Cudmore PA, Alon US, Harrison CJ: LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile. J Cell Commun Signal 2013; 7: 49–60.
26.
Liu XJ, Zhang YM, Wang SX, Liu G: Ultrastructural changes of podocyte foot processes during the remission phase of minimal change disease of human kidney. Nephrology (Carlton) 2014; 19: 392–397.
27.
van den Berg JG, van den Bergh Weerman MA, Assmann KJ, Weening JJ, Florquin S: Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901–1906.
28.
Garin EH, Laflam PF, Muffly K: Proteinuria and fusion of podocyte foot processes in rats after infusion of cytokine from patients with idiopathic minimal lesion nephrotic syndrome. Nephron Exp Nephrol 2006; 102: e105–e112.
29.
Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, Jordan SC, Yap HK: Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18: 1476–1485.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.